Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Immunic, Inc. IMUX

Healthcare  —  Biotechnology
9.35 0.03 0.32% as of 25 Sep
Market cap
$127.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Immunic, Inc. (IMUX) Business Profile

Updated before January 2025

Company Overview

Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of chronic inflammatory and autoimmune diseases. Founded in 2016, the company is headquartered in New York, USA, with additional operations in Germany. Immunic’s mission is to address unmet medical needs by focusing on the development of orally administered, small molecule therapies that target key biological pathways involved in immune system regulation.

The company was founded by Dr. Daniel Vitt, who currently serves as the Chief Executive Officer (CEO) and President. Dr. Vitt brings extensive experience in drug discovery and development, particularly in the field of immunology. Immunic’s leadership team also includes accomplished professionals with expertise in clinical development, regulatory affairs, and corporate strategy, ensuring a strong foundation for the company’s growth and innovation.

Core Business Segments

Immunic focuses on the development of novel therapies for autoimmune and inflammatory diseases. The company’s pipeline is centered around three key product candidates:

1. IMU-838 (Vidofludimus Calcium)

IMU-838 is an orally administered, selective immune modulator that inhibits the enzyme dihydroorotate dehydrogenase (DHODH). This mechanism of action is designed to reduce the proliferation of activated T and B cells while sparing normal immune function. IMU-838 is being developed for multiple indications, including:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): A chronic autoimmune disease affecting the central nervous system.
  • Ulcerative Colitis (UC): An inflammatory bowel disease causing inflammation and ulcers in the digestive tract.
  • Crohn’s Disease: Another form of inflammatory bowel disease.

2. IMU-935

IMU-935 is a highly potent and selective inverse agonist of the transcription factor RORγt, which plays a critical role in the differentiation of Th17 cells. Th17 cells are implicated in various autoimmune and inflammatory diseases. IMU-935 is being developed for conditions such as:

  • Psoriasis: A chronic autoimmune skin disease.
  • Other autoimmune disorders: Including potential applications in oncology.

3. IMU-856

IMU-856 is an orally available small molecule that targets the restoration of intestinal barrier function without suppressing the immune system. This unique approach has potential applications in:

  • Gastrointestinal Diseases: Such as celiac disease and inflammatory bowel disease.

Business Model

Immunic’s business model is centered on the research, development, and commercialization of innovative therapies for autoimmune and inflammatory diseases. The company generates revenue primarily through partnerships, licensing agreements, and potential future product sales. Immunic collaborates with academic institutions, research organizations, and pharmaceutical companies to advance its pipeline and bring its therapies to market.

The company adopts a lean operational structure, outsourcing non-core activities to specialized service providers. This approach allows Immunic to focus its resources on core competencies, such as drug discovery, clinical development, and regulatory affairs.

Strategic Direction

Immunic is committed to advancing its pipeline of product candidates through clinical development and regulatory approval. The company’s strategic priorities include:

  • Expanding Indications: Exploring additional therapeutic areas for its existing product candidates.
  • Global Market Penetration: Establishing a presence in key markets, including North America, Europe, and Asia.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its operations and supply chain.
  • Innovation: Investing in research and development to discover new therapies and expand its pipeline.

Competitive Landscape

Immunic operates in a highly competitive biopharmaceutical industry, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Biogen: A leader in therapies for neurological and autoimmune diseases.
  • Novartis: Known for its portfolio of immunology and dermatology products.
  • Celgene (a Bristol-Myers Squibb company): Focused on innovative therapies for immune-mediated diseases.
  • Other Biotech Firms: Smaller companies developing novel therapies for autoimmune and inflammatory conditions.

Immunic differentiates itself through its focus on orally administered, small molecule therapies and its innovative approach to targeting immune system pathways.

Risk Factors

Like any biopharmaceutical company, Immunic faces several risks, including:

  • Clinical Development Risks: The potential for clinical trials to fail or produce inconclusive results.
  • Regulatory Risks: Challenges in obtaining regulatory approval for its product candidates.
  • Market Dependence: Reliance on the success of its lead product candidates.
  • Supply Chain Disruptions: Potential delays or shortages in the supply of raw materials and manufacturing components.
  • Competitive Pressure: Intense competition from other companies in the biopharmaceutical sector.

Recent Developments

Immunic has made significant progress in advancing its pipeline. Recent developments include:

  • Clinical Trial Updates: Positive interim results from Phase 2 trials of IMU-838 in relapsing-remitting multiple sclerosis and ulcerative colitis.
  • Regulatory Milestones: Submission of investigational new drug (IND) applications for IMU-935 and IMU-856.
  • Partnerships: Collaboration agreements with leading academic institutions to explore new therapeutic applications.
  • COVID-19 Impact: Adjustments to clinical trial timelines and operations due to the global pandemic.

Investment Considerations

Investors considering Immunic should weigh the following factors:

Strengths:

  • Innovative Pipeline: A robust portfolio of product candidates targeting significant unmet medical needs.
  • Experienced Leadership: A management team with a proven track record in drug development.
  • Market Potential: Large addressable markets for autoimmune and inflammatory diseases.

Risks:

  • Clinical and Regulatory Uncertainty: The inherent risks associated with drug development.
  • Financial Dependence: Reliance on external funding to support operations and clinical trials.
  • Competitive Landscape: Intense competition from established players and emerging biotech firms.

Conclusion

Immunic, Inc. is well-positioned to become a leader in the biopharmaceutical industry, with a focus on innovative therapies for autoimmune and inflammatory diseases. The company’s strong pipeline, experienced leadership, and strategic vision provide a solid foundation for future growth. While challenges remain, Immunic’s commitment to addressing unmet medical needs and its potential for market success make it an attractive opportunity for investors and stakeholders alike.